By World Health Organisation
An important part of the effort involves addressing the threat to malaria treatments, and WHO is set to publish its new strategy to counter the growing problem of anti-malarial drug resistance in Africa.
Artemisinin-based combination therapy (ACT) has been the mainstay of malaria care in Africa and has played a significant role in lowering the burden of malaria over the last 2 decades.
In recent years, however, WHO has been concerned by reports of emerging drug-resistant malaria in Africa. Parasites in several areas have developed partial resistance to artemisinin – the core compound of ACTs – and there are worrying signs that they may also be resistant to other drugs that are commonly partnered with artemisinin. Vigorous measures are needed to protect their efficacy.